Amira Initiates PI trial

Amira Pharmaceuticals has initiated a Phase I clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects.

Amira Pharmaceuticals (www.amirapharm.com) has initiated a Phase I clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects.

"We are excited to begin our journey exploring the therapeutic value of AM152, a potentially novel anti-fibrotic agent. Our first step is to understand the safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this compound in normal healthy subjects," said Isabelle DeArmond, Vice President, Clinical Development. "We expect to have these studies completed by the middle of next year, and assuming positive results, we could then begin to study the therapeutic utility of AM152 in patients."

"The Amira team is very proud and excited by this important milestone," said Bob Baltera, Chief Executive Offi